Literature DB >> 31056200

The 2015 American Thyroid Association guidelines are associated with an increasing rate of hemithyroidectomy for thyroid cancer.

Timothy M Ullmann1, Katherine D Gray1, Dessislava Stefanova1, Jessica Limberg1, Jessica L Buicko1, Brendan Finnerty1, Rasa Zarnegar1, Thomas J Fahey1, Toni Beninato2.   

Abstract

BACKGROUND: In an attempt to prevent overly aggressive treatment of low-risk thyroid cancers, the American Thyroid Association changed guideline recommendations in late 2015 to state that either hemithyroidectomy or total thyroidectomy are acceptable operations for these patients. We hypothesized that surgeons would increasingly perform hemithyroidectomy after the release of these guidelines.
METHODS: The database of the National Surgery Quality Improvement Program was queried to identify all patients with thyroid cancer who were undergoing thyroidectomy between 2009 and 2017. Patients treated before the release of the 2015 American Thyroid Association guidelines were compared with those treated afterward. Temporal trends in operative rates were assessed quarterly using interrupted time series analyses.
RESULTS: A total of 35,291 patients were included in the study. Of those, 26,882 (76.2%) were female and 25,193 (71.3%) were white. After the release of the American Thyroid Association guidelines, there was an increase in hemithyroidectomy rate for patients with cancer from 17.3% to 22.0% (P < .001). Interrupted time series analysis controlling for patient factors demonstrated that quarterly growth in the hemithyroidectomy rate accelerated almost 10-fold (P < .001) after publication of the revised guidelines. Of note, there was no corresponding increase in the completion thyroidectomy rate (8.3% versus 7.9%, respectively, P = .213). Patients treated with hemithyroidectomy were more likely to be managed as outpatients (70.8% versus 57.1%, P < .001), had fewer surgical site infections (0.3% versus 0.5%, P = .050), and had fewer unplanned reintubations (0.2% versus 0.4%, P = .005).
CONCLUSION: In hospitals participating in the National Surgery Quality Improvement Program, the hemithyroidectomy rate increased significantly after the release of the 2015 American Thyroid Association guidelines. Surgeons at hospitals that participate in the National Surgery Quality Improvement Program may be changing practice patterns in response to these guidelines.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31056200     DOI: 10.1016/j.surg.2019.03.002

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  The Influence of Emotions on Treatment Decisions About Low-Risk Thyroid Cancer: A Qualitative Study.

Authors:  Susan C Pitt; Megan C Saucke; Benjamin R Roman; Stewart C Alexander; Corrine I Voils
Journal:  Thyroid       Date:  2021-11-26       Impact factor: 6.568

2.  Non-invasive follicular neoplasm with papillary-like nuclear features: a challenging and infrequent entity in Argentina.

Authors:  Melina Sabán; Norma Tolaba; Ana María Orlandi; Susana Deutsch; Fabián Pitoia; Alicia Lowenstein; María Cristina Calabrese; Andrea Cavallo; Alejandro Iotti; Marcelo Monteros Alvi; Marcelo Nallar; Ana Jaén; Silvina Figurelli; Fernando Carrizo; Antonio Colobraro; Gabriela García Tascón; María Saccoliti; Andrea Paes de Lima; Melisa Lencioni; Inés Califano; Carmen Cabezón
Journal:  Endocrine       Date:  2022-07-07       Impact factor: 3.925

Review 3.  [Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Authors:  H Dralle; F Weber; A Machens; T Brandenburg; K W Schmid; D Führer-Sakel
Journal:  Chirurgie (Heidelb)       Date:  2022-09-19

4.  Impact of the 2015 American thyroid association guidelines on treatment in older adults with low-risk, differentiated thyroid cancer.

Authors:  Whitney Sutton; Philip K Crepeau; Joseph K Canner; Shkala Karzai; Dorry L Segev; Aarti Mathur
Journal:  Am J Surg       Date:  2022-02-01       Impact factor: 3.125

5.  Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).

Authors:  Elisa Pasqual; Julie Ann Sosa; Yingxi Chen; Sara J Schonfeld; Amy Berrington de González; Cari M Kitahara
Journal:  Thyroid       Date:  2022-03-15       Impact factor: 6.506

6.  Complication Rates of Total Thyroidectomy vs Hemithyroidectomy for Treatment of Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.

Authors:  Vivian Hsiao; Tyler J Light; Abdullah A Adil; Michael Tao; Alexander S Chiu; Mary Hitchcock; Natalia Arroyo; Sara Fernandes-Taylor; David O Francis
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-06-01       Impact factor: 8.961

7.  Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007-2018.

Authors:  Asmae Toumi; Catherine DiGennaro; Vahab Vahdat; Mohammad S Jalali; G Scott Gazelle; Jagpreet Chhatwal; Rachel R Kelz; Carrie C Lubitz
Journal:  Thyroid       Date:  2021-01-18       Impact factor: 6.506

8.  Protective strategy of parathyroid glands during thyroid lobectomy: A retrospective cohort and case-control study.

Authors:  Zhichao Xing; Yuxuan Qiu; Yuan Fei; Baoying Xia; Munire Abuduwaili; Jingqiang Zhu; Anping Su
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

9.  Usefulness of 1-year of thyroid stimulating hormone suppression on additional levothyroxine in patients who underwent hemithyroidectomy with papillary thyroid microcarcinoma.

Authors:  Jin Gu Kang; Young Ah Kim; Jung Eun Choi; Soo Jung Lee; Su Hwan Kang
Journal:  Gland Surg       Date:  2019-12

10.  Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Epidemiology and Long-Term Outcomes in a Strictly Defined Cohort.

Authors:  Rainjade Chung; Haixia Guan; Cecilia Ponchiardi; Sandra Cerda; Nitin Marwaha; Osman H Yilmaz; Emma Pinjic; David McAneny; Stephanie L Lee; Frederick Thurston Drake
Journal:  Thyroid       Date:  2020-07-23       Impact factor: 6.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.